ASCO 2019: Use of broader criteria for clinical trial enrolment would double number of eligible patients with lung cancer
A study looking at 10,500 health records of advanced non-small cell lung cancer (aNSCLC) patients…
Browsing: Lung Cancer
ASCO 2019: NRG oncology trial of metformin for non-small cell lung cancer
Initial results of NRG-LU001 indicate that, although the diabetes agent metformin was well-tolerated by patients,…
ASCO 2019: Entrectinib gets edge over crizotinib against ROS1 lung cancer
Crizotinib and entrectinib are both active against ROS1 non-small cell lung cancer. But which is…
ASCO 2019: Combination checkpoint blockade effective in pre-surgical setting for early-stage lung cancers
Neoadjuvant, or pre-surgical, treatment with nivolumab plus ipilimumab resulted in an overall major pathologic response…
ASCO 2019: Pembrolizumab increases historic survival rate for certain people with advanced non-small cell lung cancer
Five-year data from the phase Ib KEYNOTE-001 clinical trial show that pembrolizumab was safe and…
ASCO 2019: 40-50 percent response rate for brigatinib after other next-gen ALK inhibitors
Crizotinib was the first drug licensed to treat ALK-positive non-small cell lung cancer (ALK NSCLC).…
Fitness may affect risk of lung, colorectal cancer and survival likelihood after diagnosis
In a recent study, adults who were the most fit had the lowest risk of…
Lung cancer under-recognized in people who have never smoked
A group of respiratory medicine and public health experts are calling for lung cancer in…
Immune system boost could prevent lung cancer
Genomic differences related to the immune system may play a key role in the early…
Biologists design new molecules to help stall lung cancer
University of Texas at Dallas scientists have demonstrated that the growth rate of the majority…